Program
netarsudil
Also written as “AR-13324 Ophthalmic Solution 0.02%”, “Netarsudil Ophthalmic Solution 0.02%” and “Netarsudil ophthalmic solution 0.02%”.
Its studies are mostly in Glaucoma, Open-Angle · Glaucoma · Fuchs' Endothelial Dystrophy · Corneal Edema, led by 2 companies.
Drug pageNetarsudil: every studyAll 33 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Alconits history only | 180 open or running | phase 4since Jan 10, 2019 | Feb 5, 2012 | none ahead |
| Price Vision Groupits history only | 20 open or running | phase 3since May 30, 2019 | May 30, 2019 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Before these, 6 studies since Feb 5, 2012.
- Mar 12, 2015Phase 1 study in Healthy SubjectsAlcon · NCT02406287 · 10 enrolled · United States
- Jun 9, 2015Named netarsudilINNProposed as its International Nonproprietary Name in WHO's List 113
- Sep 16, 2015Phase 3 study in Glaucoma, Open-AngleAlcon · NCT02558374 · 708 enrolled · United States
- Aug 15, 2016Phase 2 study in Ocular HypertensionAlcon · NCT02874846 · 12 enrolled · United States
- Jul 12, 2017Phase 2 study in Glaucoma, Open-AngleAlcon · NCT03233308 · 20 enrolled · United States
- Aug 29, 2017Phase 3 study in Glaucoma, Open-AngleAlcon · NCT03284853 · 436 enrolled · Austria, Belgium, Czechia and more
- Oct 13, 2017Phase 2 study in Glaucoma, Open-AngleAlcon · NCT03310580 · 42 enrolled · United States
- Jan 10, 2019Phase 4 study in Glaucoma, Open-AngleAlcon · NCT03808688 · 261 enrolled · United States
- Feb 15, 2019Phase 2 study in Glaucoma, Open-AngleAlcon · NCT03844945 · 215 enrolled · Japan
- May 30, 2019Price Vision Group’s first study: phase 3 study in Fuchs' Endothelial DystrophyNew to Price Vision GroupPrice Vision Group · NCT03971357 · 19 enrolled · United States
- Aug 7, 2019Phase 3 study in Fuchs' Endothelial DystrophyPrice Vision Group · NCT04051463 · 29 enrolled · United States
- Jul 31, 2020Phase 2 study in Corneal EdemaAlcon · NCT04498169 · 40 enrolled · United States
- Oct 26, 2020Phase 3 study in Glaucoma, Open-AngleAlcon · NCT04620135 · 245 enrolled · Japan
- Mar 7, 2022Phase 4 study in GlaucomaAlcon · NCT05283395 · 136 enrolled · United States
- Jul 17, 2025Phase 3 study in Ocular HypertensionAlcon · NCT07082816 · 489 enrolled · United States
TargetBeta
“Rho-associated protein kinase inhibitor”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| belumosudilrule | Sanofi | phase 4 | 26 |
Studies
All 20 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07082816Ocular Hypertension · United States | 3 | Completed | Alcon | Apr 6, 2026 | 489 |
| NCT05283395Glaucoma · United States | 4 | Completed | Alcon | Mar 22, 2023 | 136 |
| NCT04620135Glaucoma, Open-Angle · Japan | 3 | Completed | Alcon | Jul 9, 2021 | 245 |
| NCT04498169Corneal Edema · United States | 2 | Completed | Alcon | Aug 11, 2021 | 40 |
| NCT04051463Fuchs' Endothelial Dystrophy · United States | 3 | Completed | Price Vision Group | Jul 1, 2020 | 29 |
| NCT03971357Fuchs' Endothelial Dystrophy · United States | 3 | Terminated | Price Vision Group | Aug 26, 2021 | 19 |
| NCT03844945Glaucoma, Open-Angle · Japan | 2 | Completed | Alcon | Sep 19, 2019 | 215 |
| NCT03808688Glaucoma, Open-Angle · United States | 4 | Completed | Alcon | Jul 26, 2019 | 261 |
| NCT03310580Glaucoma, Open-Angle · United States | 2 | Completed | Alcon | Oct 25, 2018 | 42 |
| NCT03284853Glaucoma, Open-Angle · Austria, Belgium, Czechia and more | 3 | Completed | Alcon | Nov 6, 2020 | 436 |
| NCT03233308Glaucoma, Open-Angle · United States | 2 | Completed | Alcon | Apr 19, 2018 | 20 |
| NCT02874846Ocular Hypertension · United States | 2 | Completed | Alcon | Sep 2016 | 12 |
| NCT02558374Glaucoma, Open-Angle · United States | 3 | Completed | Alcon | Dec 2016 | 708 |
| NCT02406287Healthy Subjects · United States | 1 | Completed | Alcon | Apr 2016 | 10 |
| NCT02246764Ocular Hypertension · United States | 3 | Completed | Alcon | Dec 2016 | 93 |
| NCT02207621Ocular Hypertension · United States | 3 | Completed | Alcon | Mar 2016 | 756 |
| NCT02207491Ocular Hypertension · United States | 3 | Completed | Alcon | Mar 2015 | 411 |
| NCT01997879Healthy · United States | 1 | Completed | Alcon | Nov 2013 | 18 |
| NCT01731002Ocular Hypertension · United States | 2 | Completed | Alcon | May 2013 | 224 |
| NCT01528787Ocular Hypertension · United States | 2 | Completed | Alcon | Jul 2012 | 85 |
How it is read
Names in the registry
- “AR-13324 Ophthalmic Solution 0.02%”, 7 entries
- “Netarsudil Ophthalmic Solution 0.02%”, 3 entries
- “Netarsudil ophthalmic solution 0.02%”, 2 entries
- “Netarsudil Ophthalmic”, 2 entries
- “AR-13324 Ophthalmic Solution 0.04%”, 2 entries
Conditions, from the studies’ own filings
- Glaucoma, Open-Angle, 13 studies
- Glaucoma, 2 studies
- Fuchs' Endothelial Dystrophy, 2 studies
- Corneal Edema, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.